Erin E. Burkhart - 14 Mar 2025 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
GVP, Chief Accounting Officer
Signature
/s/ Tae Sang Yoo, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
14 Mar 2025
Net transactions value
-$57,149
Form type
4
Filing time
18 Mar 2025, 19:53:01 UTC
Previous filing
25 Feb 2025
Next filing
20 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Tax liability $57,149 -823 -6.3% $69.44 12,282 14 Mar 2025 Direct
transaction BMRN Common Stock Award $0 +5,970 +49% $0.000000 18,252 17 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) Award $0 +9,230 $0.000000 9,230 17 Mar 2025 Common Stock 9,230 $71.55 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units granted March 17, 2025. Price not applicable.
F2 Option grant vests 12/48th on March 17, 2026 and 1/48th on the 17th day of each month thereafter.